Clinical Trial Update: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy [Phase 3]

View source ↗

Summary

This clinical trial update describes a rollover extension program to evaluate the long-term safety and tolerability of open-label iptacopan (LNP023) in particip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary IgA Nephropathy | Phase 3 | Status: RECRUITING